CapForce Inc. · OTC:CFOR
CapForce — Opgen — IPO Roadshow (March 2019)
31 slides from CapForce's IPO roadshow presentation, Mar 13, 2019
Slide 1: Issuer Free Writing Prospectus
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement File No. 333-230
Slide 2: Forward-looking statements
This presentation includes statements relating to the company's Acuitas® AMR Gene Panel products, Acuitas Lighthouse® Software, FDA cleared QuickFISH® products, and commercialization plans for these products and services. These statements and other statements regarding our future plans and goals con
Slide 3: Free Writing Prospectus
Free Writing Prospectus OpGen, Inc. has filed with the SEC a registration statement (File No. 333- 230036) and a preliminary prospectus (the Preliminary Prospectus) for the offering to which this communication relates. Before you invest, you should read the Preliminary Prospectus (including the docu
Slide 4: Offering summary: NASDAQ/OPGN
NASDAQ/OPGN Offering size: Approximately $6,500,000 (100% Primary) over allotment 15% (100% Primary) 1.Research and development and regulatory activities in support of the Company’s anticipated FDA 510(k) submissions for the Acuitas® AMR Gene Panel tests and the Acuitas Lighthouse® Software. 2.Comme
Slide 5: Precision medicine company combatting antibiotic resistance
Precision medicine company focused on combatting the global antibiotic resistance crisis by leveraging molecular diagnostics, informatics, and genomic analysis Provider of rapid and actionable information about life threatening drug resistant infections Building global network of customers and partn
Slide 6: OpGen and the Investment Opportunity
OpGen and the Investment Opportunity VALIDATED, SIGNIFICANT ADDRESSING DISRUPTIVE MARKET MAJOR TECHNOLOGY OPPORTUNITY GLOBAL CRISIS Collaborations Working toaddress Multi-drug with NY Dept. of a $2B global ee eoneiciines Health, Merck, market in need of direct healthcare QIAGEN and novel solutions c
Slide 7: Addressing the Significant and Growing Global Challenge of Multi-drug Resistance
Addressing the Significant and Growing Global Challenge of Multi-drug Resistance Antibiotic resistance is one of the biggest public health challenges and leads to a significant number of patient infections, hospitalizations and deaths. It is often caused by antibiotics use or the spread of the resis
Slide 8: Large Market for Precision Medicine MDRO Solutions
Large Market for Precision Medicine MDRO Solutions Lead Product: cUTI, Clinical Isolates. Second Product Target: Lower Respiratory Infection © $2B Global Market’ . . . $2.2 Global Hospital Acquired Infection Billion . 1 * 19% CAGR: One of the fastest Testing Revenue 2012 growing U.S. molecular diagn
Slide 9: Our Solution: Rapid, Precision Medicine Antibiotic Decision Making
Our Solution: Rapid, Precision Medicine Antibiotic Decision Making Current: 2-6 days Empiric Pathogen antibiotic identification OpGen Solution Pathogen DNA Test Lighthouse Right Knowledgebase Antibiotic Acuitas® AMR Gene Panel: < 3 hours OpGen’s Solution provides answers in hours S)OpGen. 1 For Rese
Slide 10: Lighthouse: A Proprietary, Curated MDRO Genomic Knowledgebase
= AcuitasSS Lighthouse. A Proprietary, Curated MDRO Genomic Knowledgebase ita Sources feed the OpGen Anal Models which power the Commercial Applications Insights to power Drug rapid diagnostics susceptibility and optimized testing patient-specific Merck SMART interventions Pathogen Archive Lighthous
Slide 11: Productive Industry Relationships for Precision Medicine MDRO Solutions
Productive Industry Relationships for Precision Medicine MDRO Solutions Activities with top industry players provide validation for technology and bolster commercialization strategy New York State funding for OpGen and ILÚM to build a sustainable, flexible infectious diseases reporting, tracking and
Slide 12: Products and Pipeline
Products and Pipeline
Slide 13: Novel Product Pipeline
Novel Product Pipeline Q1/Q2 2019 Isolates Extended Direct from Sample Indications Lower Respiratory Infection Control (RUO) No FDA Submission AMR Prediction (AMR Gene Panel) 2H 2019 Expanded Antibiotic Indications =) OpGen
Slide 14: Insights Powered by Rapid Diagnostics & Bioinformatics
Insights Powered by Rapid Diagnostics & Bioinformatics’ RESULTS <3 hours PREDICTS RESISTANCE FOR 12 antibiotics S) OpGen, trersesesciuseony otras casnosiorcsies @ a @ eae Acu itas SN 47 resistance genes & mutations Lig ht house. Acutasit Lighthouse.
Slide 15: Predict Antibiotic Resistance - Know Local AMR Ecosystem
Predict Antibiotic Resistance’ - Know Local AMR Ecosystem Acuitassh Lighthouse. =a AcuitasS\ Lighthouse. Proprietary, cloud-based bioinformatics platform powers our ability to rapidly generate meaningful results that can change the landscape of clinical management and improves outcomes for patients
Slide 16: Initial Focus on High Risk Patient Bacterial Isolate Testing
Initial Focus on High Risk Patient Bacterial Isolate Testing Respiratory \ —~= Antibiotic Therapy - Decisions Intra Abdominal | 4 Skin & Soft Tissue / => Infection Control MDR Confirmatory & Dx Testing 1 million U.S. bacterial isolate potential testing opportunity* 90,000 estimated U.S. CRE samples
Slide 17: Management of Complicated Urinary Tract Infections
Management of Complicated Urinary Tract Infections Complicated urinary tract infections (cUTI) are increasingly difficult to treat due to rising antibiotic resistance rates. 34% annual ESBL resistance increase 2010-2014 cUTI Resistance Profile cUTI Management 1.3 millio <3Hours 15Hours 16Hours 25 Ho
Slide 18: Acuitas Lighthouse Antibiotic Resistance Prediction
Acuitas Lighthouse® Antibiotic Resistance Prediction Final training set data and program update •2 million Acuitas Lighthouse data points evaluated from Merck SMART surveillance network •41 unique prediction algorithms coded into Acuitas Lighthouse reporting engine •Final training set data supportin
Slide 19: Acuitas AMR Gene Panel
Acuitas® AMR Gene Panel Molecular test detects five pathogens and 47 resistance genes, predicting resistance for 12 antibiotics Pathogen Targets Species Identification ID Assay Isolates Correctly Identified Expected Cross-Activity e i E.coli 88 of 88 (100%) ‘some Shigella spp. E. coli “foal Sores ee
Slide 20: Acuitas Product Portfolio Regulatory Pathways
Acuitas® Product Portfolio Regulatory Pathways AMR Gene Panel u5.47 (Isolates) 510(k), FDA Class II (FDA Submission Q1/Q2 2019) Identification of bacterial nucleic acids and gene sequences associated with antimicrobial resistance in pure bacterial colonies3 and detection of forty-seven gene sequence
Slide 21: Commercialization Strategy
Commercialization Strategy
Slide 22: Acuitas Test and Software Commercialization
Acuitas Test and Software Commercialization Building Total Infectious Disease Solutions ‘ Expanded for Hospitals & Health Systems tribution Acuitas Lighthouse e Predictions 2020 Co-marketing Bacterial Isolates . Relationships FDA Clearance™ Urine (UTI) 80+ Hospital FDA Clearance” Accounts 2019 New V
Slide 23: Value-Generating Collaboration with NY Dept. of Health & ILÚM (Merck)
Value-Generating Collaboration with NY Dept. of Health & ILÚM (Merck) OpGen will work together with DoH’s Wadsworth Center and ILÚM to develop an infectious disease digital health and precision medicine platform that connects healthcare institutions to DoH and uses genomic microbiology for statewide
Slide 24: Infectious Disease Digital Health & Precision Medicine Platform
Infectious Disease Digital Health & Precision Medicine Platform NYC Pilot creates critical mass of metro area accounts and revenue generation starting Q1 2019 Q2 2019 •Hospital LDT validations and initial testing •Customized Lighthouse Software and real time data monitoring Q1 2019 •Three Tier 1 hea
Slide 25: Acuitas Rapid Test Commercial Strategy
Acuitas® Rapid Test Commercial Strategy Economics: 300-500 bed hospital 5-10 tests per day + ~3,000 tests per year + $150-$200 ASP ¥ Estimated $500 million annual U.S. revenue opportunity? 1 Assumes 1,000 hospitals with? 300 beds andLTAC facilities. These numbers are solely for illustrative purposes
Slide 26: U.S. Commercial Opportunity and Expansion Plans
U.S. Commercial Opportunity and Expansion Plans Expanding base of Acuitas® AMR Gene Panel Systems •12 system placements in Tier One Health Systems and service laboratories •New York City Acuitas installations (3 Health Systems, 35 hospitals) Acuitas Isolate/Urine indication initial launch •Post FDA
Slide 27: Developing Differentiated Precision Medicine Capabilities
Developing Differentiated Precision Medicine Capabilities OpGen is the only offering combining rapid molecular testing with fast antibiotic-resistance results1 Established Molecular players are focused on pathogen detection with limited ability to do antibiotic decision making. OpGen is paving the w
Slide 28: Financial and Operating Highlights
Financial and Operating Highlights 2018 Financial Highlights •Recurring Revenue base of $2.4 million •Completion of $860 thousand CDC Contract •$11 million cash burn Other Key Items •15,000 sq. ft. FDA cleared facility (R&D & Mfg.) •46 Employees •14 Acuitas®AMR Gene Panel System placements Guidance
Slide 29: Experienced Management Team
Experienced Management Team Evan Jones FOUNDATION Chairman & Chief Executive Officer EXDIGENE Gp foun: VY veracvte imothy Dec FORTRESS <— ThermoFisher Chief Financial Officer Faced corvis SCIENTIFIC Vadim Sapiro JITiG J. Craig Venter” Chief Information Officer STUNG oe iwstirutTe Terry Walker, Ph.D.
Slide 30: Upcoming Milestones
Upcoming Milestones Building momentum for commercialization throughout 2019 Acuitas® Gene Panel IVD FDA submissions South America commercial expansion Acuitas Lighthouse® IVD FDA submission Rapid IVD commercialization partnerships AMR Gene Panel publications/system placements NY State demonstration
Slide 31: A New Light on Antibiotic Resistance
A New Light on Antibiotic Resistance 708 Quince Orchard Road Gaithersburg, Maryland 20878 USA P 301.869.9683 F 301.869.9684 [email protected]